ClinicalTrials.gg

Program

resomelagon acetate

Also written as “AP1189, 100 mg”, “100 mg AP1189” and “AP1189, 40 mg”.

Its studies are mostly in Arthritis, Rheumatoid · Influenza, Human · Glomerulonephritis, Membranous, led by SynAct Pharma Aps.

Furthest: phase 2, since Jun 26, 20196 company-led studies, 3 open or runningNext primary completion: Aug 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SynAct Pharma Aps63 open or runningphase 2since Jun 26, 2019Jun 26, 2019Aug 1, 2027phase 2 · NCT07633288

Also a collaborator on its studies: nbcd-a-s.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2019First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT04004429 · 105 enrolled · Denmark, Norway
  2. Jun 24, 2020Phase 2 study in Nephrotic Syndrome Due to Idiopathic Membranous NephropathyNCT04456816 · 23 planned · Denmark
  3. Aug 24, 2022Phase 2 study in Arthritis, RheumatoidNCT05516979 · 127 enrolled · Moldova, Republic of
  4. Oct 31, 2022Phase 2 study in Arthritis, RheumatoidNCT05604885 · 125 enrolled · Moldova, Republic of
  5. Oct 31, 2024Phase 2 study in Arthritis, RheumatoidNCT06671054 · 240 planned · United States, Bulgaria, Denmark and more
  6. Jun 2, 2026Phase 2 study in Influenza, HumanNCT07633288 · 96 planned · Bosnia and Herzegovina, Montenegro, New Zealand and more

Ahead

  1. Aug 1, 2027Primary completion: phase 2 study in Influenza, HumanNCT07633288

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07633288Influenza, Human · Bosnia and Herzegovina, Montenegro, New Zealand and more2RecruitingAug 1, 202796
NCT06671054Arthritis, Rheumatoid · United States, Bulgaria, Denmark and more2RecruitingDec 2025240
NCT05604885Arthritis, Rheumatoid · Moldova, Republic of2CompletedAug 28, 2023125
NCT05516979Arthritis, Rheumatoid · Moldova, Republic of2CompletedJul 20, 2023127
NCT04456816Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy · Denmark2RecruitingJun 30, 202623
NCT04004429Arthritis, Rheumatoid · Denmark, Norway2CompletedNov 16, 2021105

How it is read

Names in the registry

  • “AP1189, 100 mg”, 3 entries
  • “100 mg AP1189”, 2 entries
  • “AP1189, 40 mg”, 1 entry
  • “AP1189, 70 mg”, 1 entry
  • “AP1189, 60 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.